QuantLogix ← MRNA scorecard
📅 MRNA Earnings Preview
Moderna, Inc. Common Stock
Next report (est.)
September 13, 2026
Countdown
92 days
EPS growth YoY
-34.9%
Revenue growth YoY
+260.2%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 1, 2026 ±5.7% -1.2% over-priced
November 6, 2025 ±9.0% +3.3% over-priced
August 1, 2025 ±5.7% -6.6% under-priced
May 1, 2025 ±4.2% -5.3% under-priced
November 7, 2024 ±4.4% -3.0% over-priced
August 1, 2024 ±3.9% -21.0% under-priced
May 2, 2024 ±3.8% +12.7% under-priced
November 3, 2023 ±7.6% +8.8% under-priced
Across these reports, options implied an average ±5.5% move vs an actual average of 7.7% — the stock stayed inside the implied band 38% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $-3.40 $389M $-1.3B
Q4 FY2025 $-2.11 $678M $-826M
Q3 FY2025 $-0.51 $1.0B $-200M
Q2 FY2025 $-2.13 $142M $-825M
Live 5-factor engine read: Buy · 54/100 Full scorecard →
Get alerted before every MRNA report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on MRNA before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Moderna, Inc. Common Stock (MRNA) reports in 92 days, with the next report estimated for September 13, 2026. Across the last 8 reports, options priced an average ±5.5% earnings move while the stock actually moved 7.7% on average — the market has been roughly fair on MRNA's earnings risk. Fundamentals into the print: EPS down 34.9% year-over-year, revenue up 260.2%. QuantLogix's live 5-factor engine currently reads MRNA as a buy at 54/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →